Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone

Rheumatology International

Volumn 27, Issue 10, 2007, Pages 975-979

  Fiehn, C ^a,c   Jacki, S ^a   Heilig, B ^a   Lampe, M ^a   Wiesmuller G ^a   Richter, C ^a   Rother E ^a   Rochel, E ^b   Gao, I ^a  

^a Association of Rheumatologists (Berufsverband der Rheumatologen)   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Centre for Rheumatic Diseases   (Germany)

Author keywords

DMARD; Dose intensification; Glucocorticoids; Leflunomide; Methotrexate

Indexed keywords

LEFLUNOMIDE; METHOTREXATE; PREDNISONE;

ADULT; ALOPECIA; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; EDEMA; FEMALE; HUMAN; HYPERTENSION; INFECTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; TREATMENT OUTCOME;

EID: 34447503875     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0347-0     Document Type: Article

References (19)

1. Zink A, Listing J, Niewerth M, Zeidler H (2001) The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis. Ann Rheum Dis 60:207-213
2. Thiele K, Buttgereit F, Huscher D, Zink A (2005) German collaborative arthritis centres. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum 53:740-747
3. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1164-1170
4. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM, Kaine JL, Ruderman EM, Coleman P, Curtis DL, Kopp EJ, Kantor SM, Waltuck J, Lindsley HB, Markenson A, Strand V, Crawford B, Fernando I, Simpson K, Bathon JM (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:726-733
5. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, McKendry R, Tesser J, Baker P, Wells G (1995) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 333:137-141
6. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Dougados M (2003) Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. Ann Rheum Dis 62(suppl II):ii2-ii9
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
8. van Gestel AM, Prevoo ML, 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39:34-40
9. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263-269
10. Schnabel A, Herlyn K, Burchardi C, Reinhold-Keller E, Gross WL (1996) Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol Int 15:195-200
11. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I (1998) Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 16:313-320
12. Gabriel S, Creagan E, O'Fallon WM, Jaquith J, Bunch T (1990) Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. J Rheumatol 17:460-465
13. Shiroky JB, Neville C, Skelton JD (1992) High dose intravenous methotrexate for refractory rheumatoid arthritis. J Rheumatol 19:247-251
14. Braun J, Kästner P, Flaxenberg P, Währisch J, Hanke P, Demary W, von Hinüber U, Rockwitz K, Heitz W, Pichlmeier U, Brandt A (2005) The clinical efficacy and safety of subcutaneous (s.c.) versus oral application of methotrexate (MTX) in patients with active rheumatoid arthritis (RA)-results of a randomized, controlled, double-blind, multi-center study. Arthritis Rheum 52(Suppl):ii542
15. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353:259-266
16. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V (2001) Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 44:1984-1992
17. Wassenberg S, Rau R, Steinfeld P, Zeidler H (2005) Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 52:3371-3380
18. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van der Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S (1997) Randomized comparison of combined Stepp-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309-318
19. Fiehn C, Rochel E, Ho AD, Max R (2004) Dose escalation of leflunomide (LEF) to 40 mg once daily in patients with RA and insufficient response to standard dose LEF. Ann Rheum Dis 63:746-747